BioAlliance Pharma Announces DSMB Second Positive Recommendation to Continue its Phase III Clinical Trial With Livatag® in Primary Liver Cancer
5/13/2013 11:13:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PARIS--(BUSINESS WIRE)--Regulatory News :BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today announced that the International Independent Board of Experts’ Data and Safety Monitoring Board (DSMB) again recommended continuing the ReLive Phase III trial without modification.
Help employers find you! Check out all the jobs and post your resume.
comments powered by